Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
aminolevulinic acid hydrochloride, Quantity: 10.2 mg (Equivalent: aminolevulinic acid, Qty 8 mg)
Link Medical Products Pty Ltd T/A Link Pharmaceuticals
Aminolevulinic acid hydrochloride
Patch, dermal
Excipient Ingredients: polyethylene terephthalate; polyethylene; aluminium; ethyl acetate; acrylic acid; 2-ethylhexyl acrylate; methyl acrylate; glycidyl methacrylate; 2,2'-azobisisobutyronitrile; hexane
Topical
4 patches, 8 patches
(S4) Prescription Only Medicine
Treatment of mild to moderate actinic keratoses (AK) lesions on the face and scalp (hairless areas).
Visual Identification: Square (4 sq cm) skin coloured self-adhesive patches with rounded corners; Container Type: Sachet; Container Material: Other composite material; Container Life Time: 3 Years; Container Temperature: Store below 25 degrees Celsius
Licence status A
2015-03-19
ALACARE ® _5-aminolevulinic acid (as hydrochloride) _ _ _ CONSUMER MEDICINE INFORMATION _ _ WHAT IS IN THIS LEAFLET Please read this leaflet carefully before you use Alacare. This leaflet answers some common questions about Alacare. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you taking Alacare against the benefits they expect it will have for you. IF YOU HAVE ANY CONCERNS ABOUT USING THIS MEDICINE, ASK YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET WITH THE MEDICINE. You may need to read it again. WHAT ALACARE IS USED FOR The name of your medicine is Alacare. It contains the active ingredient 5-aminolevulinic acid (as hydrochloride). Alacare is used to treat mild to moderate skin abnormalities on the head or face, called solar keratosis. These are small, rough spots which develop on the skin. They are caused by a lot of exposure to the sun over many years. They are also called actinic keratosis. Your doctor, however, may prescribe Alacare for another purpose. ASK YOUR DOCTOR IF YOU HAVE ANY QUESTIONS ABOUT WHY ALACARE HAS BEEN PRESCRIBED FOR YOU. This medicine is available only with a doctor's prescription and is to be administered by a trained health care professional. BEFORE YOU USE ALACARE _WHEN YOU MUST NOT USE IT _ DO NOT USE ALACARE IF YOU: • are allergic (hypersensitive) to 5- aminolevulinic acid, acrylic pressure sensitive adhesive or any of the other ingredients of Alacare. • suffer from a certain disease of blood metabolism known as porphyria. • were undergoing similar therapy with 5- aminolevulinic acid- containing preparations and it was unsuccessful. • have other skin conditions caused by or made worse by exposure to light. ASK YOUR DOCTOR OR PHARMACIST IF YOU ARE NOT SURE IF THIS APPLIES TO YOU. TREATMENT WITH ALACARE MAY BE LESS SUCCESSFUL IF YOUR SKIN IS AFFECTED BY: • inflammation • infection • psoriasis • eczema • cancer • tatt Read the complete document
PRODUCT INFORMATION ALACARE ® NAME OF THE MEDICINE Alacare 5-aminolevulinic acid (as hydrochloride) 8 mg dermal patch. The chemical structure of aminolevulinic acid is: *HCl Chemical name: 5-Amino-4-oxo- pentanoic acid hydrochloride The molecular formula of aminolevulinic acid hydrochloride is C 5 H 9 NO 3 * HCl and its molecular weight is 167.61. The CAS number is 5451-09-2. The white to off-white crystalline powder is freely soluble in water and slightly soluble in ethanol and methanol. DESCRIPTION Alacare ® is a dermal patch consisting of a skin tone backing foil and a self-adhesive matrix, covered by a release liner. Each dermal patch of 4 cm 2 contains 8 mg 5-aminolevulinic acid (as hydrochloride), 2 mg per cm 2 as part of a pressure sensitive adhesive patch (Durotak 387-2353, ARTG PI no: 2261), pigmented backing film (Scotchpak 1109, ARTG PI no: 11913) and polyethylene terephthalate film release liner which is removed prior to application. PHARMACOLOGY PHARMACODYNAMICS Pharmacotherapeutic group: Sensitisers used in Photodynamic/Radiation therapy, ATC Code: L01XD04 Mechanism of action: After topical application of aminolevulinic acid hydrochloride, protoporphyrin IX (PPIX) accumulates intracellularly in the treated AK lesion. The intracellular PPIX is a photoactive, fluorescing compound and, upon light activation in the presence of oxygen, singlet oxygen is formed which causes damage to cellular compartments of the light-exposed target cells, in particular the mitochondria. PHARMACOKINETICS Pharmacokinetic data from a clinical trial in patients with mild to moderate actinic keratoses on the head and/or face, who had 8 Alacare patches applied for 4h, showed a baseline corrected Cmax Alacare® Product Information - 16 February 2016 Page 1 of 7 of 16.4 µg/l and an AUC 0-24 of 101.4 µg*h/l of systemic exogenous 5-aminolevulinic acid Tmax was at 4 hours. The excretion of 5-ALA in urine during the first 12 hours after application was low. The maximum excretion was 2.06% of the total dose, the median was 1.39%. Read the complete document